ArticleFuture oncology (London, England)2023

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.

Barry Paul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.